ClinicaliQ Trial Snapshot
- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Active Not Recruiting • Phase II / Phase III • NCT05707377.
- Zanubrutinib reduced protein in urine in primary membranous nephropathy patients and was compared against standard tacrolimus treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care. Conditions: Primary Membranous Nephropathy Interventions: Zanubrutinib, Tacrolimus Lead Sponsor: BeOne Medicines Planned Enrollment: 178 participants